MIST
Milestone Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$0.78
+2.21%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.78
From 52W high−73.69%
Volume453310.00
Market cap$96.62M
P/E (TTM)—
P/S (TTM)41.2x
Div yield—
Key dataNov 4, 2026
Open
$0.78
From 52W high
−73.69%
Volume
453310.00
Market cap
$96.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
49.0
MomentumView details →
1D Return
+2.21%
YTD Return
−62.17%
SummaryUpdated Jun 1, 2026
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a Canadian biopharmaceutical company founded in 2003 and headquartered in Montréal. The company went public in May 2019 and focuses exclusively on developing cardiovascular medicines for patients with heart rhythm disorders. Milestone is currently a clinical-stage company with no approved products on the market, dedicating its resources to advancing its lead drug candidate etripamil through late-stage clinical trials for treating specific types of rapid heart rhythm conditions.
Similar companies
Latest newsMore news →
Milestone Pharmaceuticals announced that it will report its third-quarter 2026 financial results and provide a business update before the market opens on November 13, 2026, followed by an investor conference call and webcast at 8:30 a.m. ET.1d agoMilestone Pharmaceuticals announced data showing that CARDAMYST nasal spray converted approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation to normal heart rhythm within 30 minutes.2d agoMilestone Pharmaceuticals announced that data and program updates on CARDAMYST (etripamil) nasal spray will be presented at three upcoming cardiovascular medical meetings.16d ago